Cancel
Peter Blume-Jensen
CEO, President, FounderChairperson
@
Acrivon Therapeutics
12kg23w7q694k@kxx5621.dhx
Sign up to see email
See Linkedin
Known information
- Has three decades of precision oncology R&D and in-licensing leadership experience.
- Has expertise in oncogenic kinase signaling, phosphoproteomics, and clinical drug and biomarker development.
- Previously held executive positions at Serono, Merck & Co., and Daiichi Sankyo.
- Served as Chief Scientific Officer at Metamark Genetics.
- Developed the first marketed prostate test ProMark®.
- Invented the AP3 platform and OncoSignature patient selection method.
- Serves on the Scientific Advisory Board for several private biotech companies and academic institutions.
- Authored a highly cited review on Oncogenic Kinase Signaling in Nature (2001).
- Received an M.D. from Copenhagen University Medical School, Denmark.
- Earned a Ph.D. from The Ludwig Institute for Cancer Research, Uppsala, Sweden.
- Completed a Post-Doctoral Fellowship under Tony Hunter at the Salk Institute, La Jolla, CA.
About Acrivon Therapeutics
Acrivon Therapeutics develops precision oncology medicines using a proprietary proteomics-based platform, with its lead candidate ACR-368 in a Phase 2 trial for multiple tumor types.
Report inaccurate information